Catalyst Pharmaceuticals (NASDAQ:CPRX) Analyst Rating Consensus

Catalyst Pharmaceuticals (NASDAQ:CPRX) has received a short term rating of buy from experts at Zacks with a rank of 2. The stock has been rated an average of 1.5 by 4 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 1 Brokerage Firms have advised hold.

Other Equity analysts have also commented on the company shares. In a research note released to the investors, Piper Jaffray downgrades its rating on Catalyst Pharmaceuticals (NASDAQ:CPRX).The analysts at the brokerage house have a current rating of Neutral on the shares. Earlier, the shares were rated a Overweight by the brokerage firm. The rating by the firm was issued on April 26, 2016.

Catalyst Pharmaceuticals (NASDAQ:CPRX): The mean estimate for the short term price target for Catalyst Pharmaceuticals (NASDAQ:CPRX) stands at $3.5 according to 4 Analysts. The higher price target estimate for the stock has been calculated at $6 while the lower price target estimate is at $1.

Catalyst Pharmaceuticals (NASDAQ:CPRX) rose 2.61% or 0.0217 points on Tuesday and made its way into the gainers of the day. After trading began at $0.83 the stock was seen hitting $0.89 as a peak level and $0.82 as the lowest level. The stock ended up at $0.8516. The daily volume was measured at 1,745,007 shares. The 52-week high of the share price is $5.8 and the 52-week low is $0.51. The company has a market cap of $71 million.

Shares of Catalyst Pharmaceuticals, Inc. rose by 21.66% in the last five trading days and 41.93% for the last 4 weeks. Catalyst Pharmaceuticals, Inc. has dropped 31.87% during the last 3-month period . Year-to-Date the stock performance stands at -65.24%.

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. Firdapse is used for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). CPP-115 is used for the treatment of addiction and epilepsy. CPP-109 is used to treat addiction. The Company is conducting a Phase III trial to determine the safety and efficacy of Firdapse in the treatment of LEMS. CPP-115 has been granted Orphan Drug Designation by the food and drug administration (FDA) for the treatment of infantile spasms and Orphan Medicinal Product Designation in the European Union, for West syndrome (a form of infantile spasms).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.